Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July

  • Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2
  • The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration
  • The study’s main objective is to evaluate Lexaria’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug, semaglutide, currently commercially available as Rybelsus(R)
  • The commencement of the pilot study shows Lexaria’s commitment to its promise to focus on GLP-1 studies for 2024, along with its confidence in its DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study aims to evaluate the company’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1) drug semaglutide, which is currently commercially available in the branded product Rybelsus(R) (

This second round of dosing utilized Rybelsus processed with DehydraTECH and is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database (“FDA IID”), which was administered with swallowed capsules. All nine study participants were successfully dosed, building on the initial study arm, which used a positive control Rybelsus swallowed tablet, whereas the third arm will explore an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.

This third and final study arm will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can be absorbed into the bloodstream at any level systemically into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed pill administration. This study is set to be completed in early July. If successful, this study will help remedy the downsides of swallowed administration, which is heavily impacted by the stomach’s acidic environment. This environment significantly degrades GLP-1 drugs swallowed, resulting in meager blood absorption rates of less than 1% when absorption technology is not used.

This move aligns with Lexaria’s plan to focus on GLP-1 studies for the 2024 calendar year. It also speaks to its commitment and overall confidence in the potential of its DehydraTECH technology. It is an important milestone for the company, mainly since, at the very beginning, the GLP-1 studies were considered a “high-risk” program, according to its CEO, Chris Bunka. This was mainly attributed to the fact that the study fell under a class of drugs considered “large molecules,” a class that the company had never explored before, especially given its focus on “small molecules” (

So far, Lexaria has achieved great success with its GLP-1 studies. In addition, the rising interest in GLP-1 drugs, owing to their health benefits, has seen the company double down on this research going forward. The successful completion of the second round of dosing for its GLP-H24-2 human pilot study indicates this commitment while ushering in what’s to come for the company.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in Lexaria Bioscience Corp. LEXX. Bookmark the permalink.

Comments are closed.